FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2221164499> ?p ?o ?g. }

• W2221164499 endingPage "140" @default.
• W2221164499 startingPage "131" @default.
• W2221164499 abstract "PurposeIt is clear that triple-negative breast cancer (TNBC) tumors are heterogeneous group, but clinically important sub-sets have begun to emerge. We investigate the immunohistochemical expression of androgen receptor (AR) among those hormonal insensitive groups which have only the option of chemotherapy. Exploiting this knowledge for therapy has been challenging.Patients & methodsSeventy seven patients with TNBC subtype, treated from January 2009 until February 2011 were evaluated for AR expression where AR-positive expression group (⩾10% nuclear stained cells) was conducted to receive anti-androgen therapy post adjuvant chemotherapy (Bicalutamide “Casodex®”) 50 mg, once daily with or without meals at the same time each day, to date. AR expression was correlated with other prognostic factors and survival (disease free survival (DFS) and overall survival (OS)). Cox proportional hazard model was used to assess variables in the multivariate analysis.ResultsThe median age in the present study was 35.6 year (19–63 years). The median follow-up period was 24 months (3–60 months). AR-positive expression in the present study was (21⧹77) 27.27% correlated with clinical outcomes, for recurrent event (n = 4, 19.05%), (P = 0.000, HR 12.750, Cl 95% 3.668–44.318) and for death event, no body died in AR positive expression group (P = 0.000, HR 0.644, Cl 95% 0.533–0.779). Improved survival with AR-positive expression group for 2-year and 3-year DFS was 85% and 78% respectively with (P = <0.001, Cl 95% 39.17–51.39) and for OS at 2-year and 3-year was 100% (P = 0.0005). In univariate and multivariate analysis, AR positive expression with anti-androgen therapy in TNBC patients in our present study had retained their independent prognostic value for DFS (P = 0.0006, HR 4.659, Cl 95% 1.553–13.977). Bicalutamide was well-tolerated therapy with no grade 3/4 treatment-related adverse events.ConclusionsBicalumide is well tolerated in AR positive TNBC subtype patients and could offer an alternative to cytotoxic chemotherapy in those patients with better OS and DFS." @default.
• W2221164499 created "2016-06-24" @default.
• W2221164499 creator A5035685243 @default.
• W2221164499 creator A5067853578 @default.
• W2221164499 creator A5084845462 @default.
• W2221164499 date "2016-06-01" @default.
• W2221164499 modified "2023-10-12" @default.
• W2221164499 title "Androgen receptor expression as a prognostic and predictive marker in triple-negative breast cancer patients" @default.
• W2221164499 cites W1497822707 @default.
• W2221164499 cites W1522435592 @default.
• W2221164499 cites W1536290683 @default.
• W2221164499 cites W1598969217 @default.
• W2221164499 cites W1972659703 @default.
• W2221164499 cites W1976263258 @default.
• W2221164499 cites W1981672008 @default.
• W2221164499 cites W1984988410 @default.
• W2221164499 cites W1986989859 @default.
• W2221164499 cites W1989663680 @default.
• W2221164499 cites W1995224853 @default.
• W2221164499 cites W2009302893 @default.
• W2221164499 cites W2035921832 @default.
• W2221164499 cites W2039680999 @default.
• W2221164499 cites W2041497771 @default.
• W2221164499 cites W2044638220 @default.
• W2221164499 cites W2045909049 @default.
• W2221164499 cites W2056556973 @default.
• W2221164499 cites W2065796923 @default.
• W2221164499 cites W2070480410 @default.
• W2221164499 cites W2078400569 @default.
• W2221164499 cites W2078461309 @default.
• W2221164499 cites W2079096506 @default.
• W2221164499 cites W2082326948 @default.
• W2221164499 cites W2085181480 @default.
• W2221164499 cites W2086519305 @default.
• W2221164499 cites W2090590858 @default.
• W2221164499 cites W2095933146 @default.
• W2221164499 cites W2096027508 @default.
• W2221164499 cites W2099744380 @default.
• W2221164499 cites W2101673433 @default.
• W2221164499 cites W2102596641 @default.
• W2221164499 cites W2118605519 @default.
• W2221164499 cites W2119401526 @default.
• W2221164499 cites W2123210834 @default.
• W2221164499 cites W2132360977 @default.
• W2221164499 cites W2135847690 @default.
• W2221164499 cites W2140834095 @default.
• W2221164499 cites W2140835320 @default.
• W2221164499 cites W2144247813 @default.
• W2221164499 cites W2157285286 @default.
• W2221164499 cites W2165662097 @default.
• W2221164499 cites W2169260048 @default.
• W2221164499 cites W2170602872 @default.
• W2221164499 cites W80971072 @default.
• W2221164499 doi "https://doi.org/10.1016/j.ajme.2015.06.002" @default.
• W2221164499 hasPublicationYear "2016" @default.
• W2221164499 type Work @default.
• W2221164499 sameAs 2221164499 @default.
• W2221164499 citedByCount "6" @default.
• W2221164499 countsByYear W22211644992018 @default.
• W2221164499 countsByYear W22211644992019 @default.
• W2221164499 countsByYear W22211644992022 @default.
• W2221164499 countsByYear W22211644992023 @default.
• W2221164499 crossrefType "journal-article" @default.
• W2221164499 hasAuthorship W2221164499A5035685243 @default.
• W2221164499 hasAuthorship W2221164499A5067853578 @default.
• W2221164499 hasAuthorship W2221164499A5084845462 @default.
• W2221164499 hasBestOaLocation W22211644991 @default.
• W2221164499 hasConcept C121608353 @default.
• W2221164499 hasConcept C126322002 @default.
• W2221164499 hasConcept C143998085 @default.
• W2221164499 hasConcept C204232928 @default.
• W2221164499 hasConcept C207103383 @default.
• W2221164499 hasConcept C2776694085 @default.
• W2221164499 hasConcept C2780110267 @default.
• W2221164499 hasConcept C2780192828 @default.
• W2221164499 hasConcept C2780962315 @default.
• W2221164499 hasConcept C38180746 @default.
• W2221164499 hasConcept C44249647 @default.
• W2221164499 hasConcept C50382708 @default.
• W2221164499 hasConcept C530470458 @default.
• W2221164499 hasConcept C61367390 @default.
• W2221164499 hasConcept C71924100 @default.
• W2221164499 hasConceptScore W2221164499C121608353 @default.
• W2221164499 hasConceptScore W2221164499C126322002 @default.
• W2221164499 hasConceptScore W2221164499C143998085 @default.
• W2221164499 hasConceptScore W2221164499C204232928 @default.
• W2221164499 hasConceptScore W2221164499C207103383 @default.
• W2221164499 hasConceptScore W2221164499C2776694085 @default.
• W2221164499 hasConceptScore W2221164499C2780110267 @default.
• W2221164499 hasConceptScore W2221164499C2780192828 @default.
• W2221164499 hasConceptScore W2221164499C2780962315 @default.
• W2221164499 hasConceptScore W2221164499C38180746 @default.
• W2221164499 hasConceptScore W2221164499C44249647 @default.
• W2221164499 hasConceptScore W2221164499C50382708 @default.
• W2221164499 hasConceptScore W2221164499C530470458 @default.
• W2221164499 hasConceptScore W2221164499C61367390 @default.
• W2221164499 hasConceptScore W2221164499C71924100 @default.
• W2221164499 hasIssue "2" @default.

• next